BioCentury
ARTICLE | Clinical News

Bispectral index technology: Phase IV started

April 3, 2006 7:00 AM UTC

Aspect began the double-blind, dose-escalation, U.S. Phase IV BRITE trial in 375 patients with the most recent episodes lasting >2 weeks to predict response to escitalopram, bupropion and a combined t...